Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEGS1646

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 4	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 5	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 7	AUG 27	USPATOLD now available on STN
NEWS 8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 10	SEP 13	FORIS renamed to SOFIS
NEWS 11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 12	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 13	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS 14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 15	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 16	OCT 19	BEILSTEIN updated with new compounds
NEWS 17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS 18	NOV 19	WPIX enhanced with XML display format
NEWS 19	NOV 30	ICSD reloaded with enhancements
NEWS 20	DEC 04	LINPADOCDB now available on STN
NEWS 21	DEC 14	BEILSTEIN pricing structure to change
NEWS 22	DEC 17	USPATOLD added to additional database clusters
NEWS 23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS 24	DEC 17	DGENE now includes more than 10 million sequences
NEWS 25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 27	DEC 17	CA/CAplus enhanced with new custom IPC display formats
NEWS 28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS 29	JAN 02	STN pricing information for 2008 now available
NEWS 30	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 31	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 32	JAN 28	MARPAT searching enhanced
NEWS 33	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS 34	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment

```
 NEWS 35  JAN 28  MEDLINE and LMEDLINE reloaded with enhancements
 NEWS 36  FEB 08  STN Express, Version 8.3, now available


 NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 24 JANUARY 2008

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:26:33 ON 20 FEB 2008

=> File .Gerry2MBCE
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'MEDLINE' ENTERED AT 10:27:15 ON 20 FEB 2008

FILE 'BIOSIS' ENTERED AT 10:27:15 ON 20 FEB 2008
Copyright (c) 2008 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 10:27:15 ON 20 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 10:27:15 ON 20 FEB 2008
Copyright (c) 2008 Elsevier B.V. All rights reserved.

=> S Propyene glycol (S) Tonicity (S) (liqiud formulation) AND pd<=20030708
   2 FILES SEARCHED...
L1             0 PROPYENE GLYCOL (S) TONICITY (S) (LIQIUD FORMULATION) AND PD<=20
                 030708

=> S (Propylene glycol) (S) Tonicity (S) (liquid formulation) AND pd<=20030708
   2 FILES SEARCHED...
L2             0 (PROPYLENE GLYCOL) (S) TONICITY (S) (LIQUID FORMULATION) AND
                 PD<=20030708

=> S (Propylene glycol) (P) Tonicity (P) (liquid formulation) AND pd<=20030708
   2 FILES SEARCHED...
L3             0 (PROPYLENE GLYCOL) (P) TONICITY (P) (LIQUID FORMULATION) AND
                 PD<=20030708

=> S (Propylene glycol) (S) (liquid formulation) AND pd<=20030708
   2 FILES SEARCHED...
L4            21 (PROPYLENE GLYCOL) (S) (LIQUID FORMULATION) AND PD<=20030708

=> Dup Rem
```

```
ENTER L# LIST OR (END):L
ENTER L# LIST OR (END):L4
PROCESSING COMPLETED FOR L4
L5           17 DUP REM L4 (4 DUPLICATES REMOVED)
                ANSWERS '1-3' FROM FILE BIOSIS
                ANSWERS '4-17' FROM FILE CAPLUS

=> D ti l5 1-17

L5   ANSWER 1 OF 17  BIOSIS  COPYRIGHT (c) 2008 The Thomson Corporation  on STN
     DUPLICATE 1
TI   A STABILITY STUDY OF CLINDAMYCIN HYDRO CHLORIDE AND CLINDAMYCIN PHOSPHATE
     SALTS IN TOPICAL FORMULATIONS.

L5   ANSWER 2 OF 17  BIOSIS  COPYRIGHT (c) 2008 The Thomson Corporation  on STN
     DUPLICATE 2
TI   ASPIRIN DEGRADATION IN MIXED POLAR SOLVENTS.

L5   ANSWER 3 OF 17  BIOSIS  COPYRIGHT (c) 2008 The Thomson Corporation  on STN
TI   Diffusion of herbicides through plastic film.

L5   ANSWER 4 OF 17  CAPLUS  COPYRIGHT 2008 ACS on STN
TI   Stabilizing biomolecules in liquid formulations

L5   ANSWER 5 OF 17  CAPLUS  COPYRIGHT 2008 ACS on STN
TI   Stable viscous liquid formulations of amlexanox for the prevention and
     treatment of mucosal diseases and disorders

L5   ANSWER 6 OF 17  CAPLUS  COPYRIGHT 2008 ACS on STN
TI   Transdermal Delivery of Highly Lipophilic Drugs: In Vitro Fluxes of
     Antiestrogens, Permeation Enhancers, and Solvents from Liquid Formulations

L5   ANSWER 7 OF 17  CAPLUS  COPYRIGHT 2008 ACS on STN
TI   Pharmaceutical compositions containing chelates and reducing agents with
     improved stability

L5   ANSWER 8 OF 17  CAPLUS  COPYRIGHT 2008 ACS on STN
TI   Stable liquid formulations of high vitamin E content

L5   ANSWER 9 OF 17  CAPLUS  COPYRIGHT 2008 ACS on STN
TI   Antiperspirant formulation for porous applicator

L5   ANSWER 10 OF 17  CAPLUS  COPYRIGHT 2008 ACS on STN
TI   Nebulizer-compatible liquid formulations for pulmonary delivery of
     glucocorticoids: pre-formulation studies

L5   ANSWER 11 OF 17  CAPLUS  COPYRIGHT 2008 ACS on STN
TI   Pharmaceutical compositions containing lamivudine and a preservative

L5   ANSWER 12 OF 17  CAPLUS  COPYRIGHT 2008 ACS on STN
TI   Stable particle in liquid formulations comprising sugar glass

L5   ANSWER 13 OF 17  CAPLUS  COPYRIGHT 2008 ACS on STN
TI   Compositions comprising an HIV protease inhibitor such as VX 478 and a
     water soluble vitamin e compound such as vitamin E-TPGS

L5   ANSWER 14 OF 17  CAPLUS  COPYRIGHT 2008 ACS on STN
TI   Tastemasked liquid pharmaceuticals containing sugars and hydrogenated
     maltose and polyhydroxy alcohols

L5   ANSWER 15 OF 17  CAPLUS  COPYRIGHT 2008 ACS on STN
TI   Stabilized isothiazolone liquid formulation
```

L5 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
TI Stabilized aqueous liquid formulations of phytase and their use in feed preparation for monogastric animals

L5 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
TI Metal-acid complexes with members of the tetracycline family. II. Development of stable preconstituted parenteral formulations

=> D ibib abs l5 1-17

L5 ANSWER 1 OF 17 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
DUPLICATE 1
ACCESSION NUMBER: 1984:337147 BIOSIS
DOCUMENT NUMBER: PREV198478073627; BA78:73627
TITLE: A STABILITY STUDY OF CLINDAMYCIN HYDRO CHLORIDE AND CLINDAMYCIN PHOSPHATE SALTS IN TOPICAL FORMULATIONS.
AUTHOR(S): MIGTON J M [Reprint author]; KENNON L; SIDEMAN M; PLAKOGIANNIS F M
CORPORATE SOURCE: DIV OF PHARMACEUTICS AND INDUSTRIAL SCI, ARNOLD AND MARIE SCHWARTZ COLL OF PHARMACY AND HEALTH SCI, LIU, 75 DEKALB AVE, BROOKLYN, NY 11201, USA
SOURCE: Drug Development and Industrial Pharmacy, (1984) Vol. 10, No. 4, pp. 563-574. CODEN: DDIPD8. ISSN: 0363-9045.
DOCUMENT TYPE: Article
FILE SEGMENT: BA
LANGUAGE: ENGLISH
AB The stability of clindamycin hydrochloride and clindamycin phosphate [used in the treatment of acne vulgaris] was studied in topical liquid formulations prepared with the following solvents: solvent a (70% isopropanol, 10% propylene glycol and 20% water); solvent B (48% isopropanol, polyoxyethelene ethers, acetone, salicylic acid and allantoin); solvent C (40% alcohol, acetone, polysorbate 20, fragrance and water); and standard (50% isopropyl alcohol, propylene glycol and water) in glass and plastic containers at 25°, 40°, and 50° C. In general, better stability was obtained in glass containers than in plastic containers. At 25° C both the clindamycin hydrochloride and phosphate formulations in solvent B showed poorer stability than in the other solvents irrespective of the type of container, while formulations in solvent C showed the best stability. The effect of the pH on the stability of the formulations was determined. At pH values below 4 the stability of all formulations decreased.

L5 ANSWER 2 OF 17 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
DUPLICATE 2
ACCESSION NUMBER: 1984:309646 BIOSIS
DOCUMENT NUMBER: PREV198478046126; BA78:46126
TITLE: ASPIRIN DEGRADATION IN MIXED POLAR SOLVENTS.
AUTHOR(S): CHANG R-K [Reprint author]; WHITWORTH C W
CORPORATE SOURCE: COLL PHARM, UNIV GA, ATHENS, GA 30602, USA
SOURCE: Drug Development and Industrial Pharmacy, (1984) Vol. 10, No. 3, pp. 515-526. CODEN: DDIPD8. ISSN: 0363-9045.
DOCUMENT TYPE: Article
FILE SEGMENT: BA
LANGUAGE: ENGLISH
AB Degradation studies were conducted 0.2% w/v [wt/vol] aspirin [an antipyretic, antiinflammatory and analgesic agent] liquid formulation in a wide range of water-propylene

glycol mixtures and water-triethylene glycol diacetate mixtures at 4 temperatures. The effect of a surfactant, polyoxyethylene (20) sorbitan monolaurate, on aspirin stability was also investigated. There was a linear relationship between water content and degradation rate constants. The surfactant increased aspirin degradation in all formulations. Formulations containing the higher concentration of the surfactant showed the greater aspirin decomposition.

L5 ANSWER 3 OF 17 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN
ACCESSION NUMBER: 1964:32033 BIOSIS
DOCUMENT NUMBER: PREV19644500032037; BA45:32037
TITLE: Diffusion of herbicides through plastic film.
AUTHOR(S): BRIDGES, W. R.; SANDERS, HERMAN O.
CORPORATE SOURCE: U. S. Bur. Sport Fish and Wildlife, Denver, Colo., USA
SOURCE: PROGR FISH CULT, (1963) Vol. 25, No. 4, pp. 213-214.
DOCUMENT TYPE: Article
FILE SEGMENT: BA
LANGUAGE: Unavailable
ENTRY DATE: Entered STN: May 2007
Last Updated on STN: May 2007

AB Laboratory tests with various herbicides and polyethylene and saran film demonstrated that herbicides will diffuse through these materials in aquatic situations. Tests with a liquid formulation of the propylene glycol butyl ether esters of 2,4-D and polyethylene bags of 0.003-in. thickness, revealed that when 10 mg. of the herbicide was added to 5 1. of water in the bag and the bag was immersed in 10 1. of water, and equilibrium of herbicide in the water inside and outside the bag was reached after 96 hours. Similarly conducted tests with polyvinyl chloride film indicated that it is an effective barrier. Diffusion through the vinyl film did not occur in tests using the propylene glycol butyl ether esters of 2,4-D and the butoxyethanol ester of silvex. ABSTRACT AUTHORS: W. R. Bridges

L5 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:428730 CAPLUS
DOCUMENT NUMBER: 137:10994
TITLE: Stabilizing biomolecules in liquid formulations
INVENTOR(S): Cowan, Siu Man L.; McGinnis, Vincent; Palmer, Donna T.; Risser, Steven M.; Brody, Richard S.
PATENT ASSIGNEE(S): Battelle Memorial Institute, USA
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002043750	A2	20020606	WO 2001-US48834	20011030 <--
WO 2002043750	A3	20021031		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2430137	A1	20020606	CA 2001-2430137		20011030 <--
AU 2002036641	A	20020611	AU 2002-36641		20011030 <--
EP 1343521	A2	20030917	EP 2001-986180		20011030
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004526674	T	20040902	JP 2002-545720		20011030
US 2002102218	A1	20020801	US 2001-20798		20011130 <--
US 2002110524	A1	20020815	US 2001-20799		20011130 <--
US 7141542	B2	20061128			
NZ 526135	A	20050930	NZ 2001-526135		20011130
MX 2003PA04883	A	20040504	MX 2003-PA4883		20030530
US 2005112092	A1	20050526	US 2004-15201		20041217
PRIORITY APPLN. INFO.:			US 2000-250491P	P	20001201
			WO 2001-US48834	W	20011030
			US 2001-20798	B1	20011130

AB The invention is directed to a stable formulation of a biol. active protein useful for aerosol delivery to the respiratory tract of a patient in need of treatment comprising: (a) a carrier liquid comprising from about 10 % to from about 100 % V/V water and from about 0 % to from about 90 % V/V of an organic liquid; (b) a biol. effective amount of a protein suspended or dissolved in a carrier liquid; and (c) a stabilizing effective amount of a derivatized carbohydrate stabilizing agent suspended or dissolved in said carrier liquid The stable formulations of the invention may optionally contain about 0.1 % to about 5.0 % weight/volume of a pharmaceutically acceptable excipient. In an ethanol-water (80:20) carrier liquid the preferred stabilizer for insulin is C12-glucose, while in a totally aqueous carrier liquid the preferred stabilizer is C8 glucose or C8 trehalose.

L5 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:575762 CAPLUS
DOCUMENT NUMBER: 137:129916
TITLE: Stable viscous liquid formulations of amlexanox for the prevention and treatment of mucosal diseases and disorders
INVENTOR(S): Jacob, Jeremy
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 22 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2002103219	A1	20020801	US 2001-971562		20011004 <--
PRIORITY APPLN. INFO.:			US 2000-238175P	P	20001005

AB Present invention concerns stable viscous liquid formulations of amlexanox for the prevention and treatment of mucosal diseases and disorders. The mucoadhesive of the present invention may be a linear or crosslinked polymer such as polyacrylic acid, hydroxyalkyl cellulose, dextran sulfate, and etc. An object of the present invention is to provide a convenient and effective dosage form for Amlexanox in the treatment of skin mucous disorders. This form allows for an ED of the pharmaceutical to be applied to the lesions being treated over an extended period. Thus, a viscous, mucoadhesive aqueous composition contained water 91.26, KOH 0.60, benzyl alc. 1.50, Polysorbate-60 0.05, Carbopol 971P 0.35, H3PO4 0.13, citric acid 0.05, saccharin sodium 0.40, amlexanox 0.50, and glycerin 5.20% by weight

L5 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:454133 CAPLUS
DOCUMENT NUMBER: 138:226493
TITLE: Transdermal Delivery of Highly Lipophilic Drugs: In Vitro Fluxes of Antiestrogens, Permeation Enhancers, and Solvents from Liquid Formulations
AUTHOR(S): Funke, Adrian P.; Schiller, Roman; Motzkus, Hans W.; Guenther, Clemens; Mueller, Rainer H.; Lipp, Ralph
CORPORATE SOURCE: Pharmaceutical Development, Schering AG, Berlin, 13342, Germany
SOURCE: Pharmaceutical Research (2002), 19(5), 661-668
CODEN: PHREEB; ISSN: 0724-8741
PUBLISHER: Kluwer Academic/Plenum Publishers
DOCUMENT TYPE: Journal
LANGUAGE: English
GI





AB Highly lipophilic basic drugs, the antiestrogens AE 1 (I) (log P = 5.82) and AE 2 (II) (log P = 7.8) shall be delivered transdermally. Transdermal permeation of drugs, enhancers, and solvents from various fluid formulations were characterized by in-vitro permeation studies through excised skin of hairless mice. Furthermore, differential scanning calorimetry (DSC) measurements of skin lipid phase transition temps. were conducted. Transdermal flux of highly lipophilic drugs was extraordinarily enhanced by the unique permeation enhancer combination propylene glycol-lauric acid (9 & 1): steady-state fluxes of AE 1 and AE 2 were as high as 5.8 μg·cm-2·h-1 and 3.2 μg·cm-2·h-1, resp. This dual enhancer formulation also resulted in a marked increase in the transdermal fluxes of the enhancers. Furthermore, skin lipid phase transition temps. were significantly reduced by treatment with this formulation. Transdermal delivery of highly lipophilic drugs can be realized by using the permeation enhancer combination propylene glycol-lauric acid. The extraordinary permeation enhancement for highly lipophilic drugs by this formulation is due to mutual permeation enhancement of these two enhancers and their synergistic lipid-fluidizing activity in the stratum corneum.

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:247182 CAPLUS
DOCUMENT NUMBER: 134:271268
TITLE: Pharmaceutical compositions containing chelates and reducing agents with improved stability
INVENTOR(S): Khanolkar, Jayant Eknath
PATENT ASSIGNEE(S): Procter & Gamble Co., USA
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001022967	A1	20010405	WO 2000-US26402	20000926 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002082307	A1	20020627	US 1999-467333	19991220 <--
CA 2385990	A1	20010405	CA 2000-2385990	20000926 <--
BR 2000014441	A	20020611	BR 2000-14441	20000926 <--
EP 1216044	A1	20020626	EP 2000-970493	20000926 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
HU 2002002797	A2	20030128	HU 2002-2797	20000926 <--
HU 2002002797	A3	20040528		
JP 2003510279	T	20030318	JP 2001-526179	20000926 <--
AU 770376	B2	20040219	AU 2000-79865	20000926
ZA 2002001892	A	20021003	ZA 2002-1892	20020307 <--
IN 2002KN00328	A	20050923	IN 2002-KN328	20020308
MX 2002PA03312	A	20021004	MX 2002-PA3312	20020327 <--
AU 2004200445	A1	20040304	AU 2004-200445	20040206

PRIORITY APPLN. INFO.:		
US 1999-156540P	P	19990929
US 1999-467333	A	19991220
US 2000-179289P	P	20000131
US 1999-115378P	P	19990111
AU 2000-28475	A3	20000110
WO 2000-US26402	W	20000926

AB The present invention pertains to improved stability of compns. that deliver drugs. These compns. have exceptional stability when used in various product forms including liquid elixirs placed into the mouth and eventually swallowed, or can be delivered via liquid-filled lozenges, metered liquid dosing devices, atomizers and liquid-releasing, edible capsules. Such compns. are particularly useful for treating symptoms associated with respiratory illnesses. Thus, a liquid formulation contained dextromethorphan 3.425, sodium hexametaphosphate 0.050, propylene glycol 95.355, sucralose 0.300, Pro-Sweet liquid-K 0.700, monosodium glycyrrhizinate 0.050, flavor 0.015, colorant 0.005, and sodium thiosulfate 0.100% by weight

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:895653 CAPLUS
DOCUMENT NUMBER: 136:25112
TITLE: Stable liquid formulations of high vitamin E content
INVENTOR(S): Crepeau, Michel Andre
PATENT ASSIGNEE(S): Aventis Animal Nutrition, S.A., Fr.
SOURCE: U.S., 3 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6329423	B1	20011211	US 2000-590804	20000609 <--
WO 2001070044	A1	20010927	WO 2001-EP3952	20010323 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1265496	A1	20021218	EP 2001-933800	20010323 <--
EP 1265496	B1	20051102		
AT 308251	T	20051115	AT 2001-933800	20010323
ES 2251481	T3	20060501	ES 2001-933800	20010323
US 2004018217	A1	20040129	US 2003-239503	20030103
US 6852332	B2	20050208		

PRIORITY APPLN. INFO.:		
EP 2000-106397	A	20000324
US 2000-590804	A	20000609
WO 2001-EP3952	A	20010323

AB A stable liquid vitamin E formulation having at least 60% vitamin E comprises water 0.5-3, potassium sorbate 0.05-0.15, propylene glycol 0.3-0.7, 1-propanol 15-20, polyethylene glycol 400 monooleate 12-17 and vitamin E oil 60-70% by weight The formulation is free of polyoxyethylene sorbitan monooleate and has a viscosity at 20° of <about 1000 cPs.

L5 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:748166 CAPLUS
DOCUMENT NUMBER: 131:341784
TITLE: Antiperspirant formulation for porous applicator
INVENTOR(S): Schamper, Thomas; Moghe, Bhalchandra; Barr, Morton L.; Wu, Ching-min Kimmy
PATENT ASSIGNEE(S): Colgate-Palmolive Company, USA
SOURCE: U.S., 11 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5989531	A	19991123	US 1998-191897	19981113 <--
CA 2349167	A1	20000525	CA 1999-2349167	19991102 <--
WO 2000028956	A1	20000525	WO 1999-US25570	19991102 <--

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

BR 9915298	A	20010807	BR 1999-15298	19991102	<--
EP 1128803	A1	20010905	EP 1999-957489	19991102	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, RO					
HU 2001004518	A2	20020429	HU 2001-4518	19991102	<--
HU 2001004518	A3	20030428			
AU 760372	B2	20030515	AU 2000-15183	19991102	<--
ZA 2001003811	A	20020510	ZA 2001-3811	20010510	<--
MX 2001PA04860	A	20010731	MX 2001-PA4860	20010514	<--
PRIORITY APPLN. INFO.:			US 1998-191897 A	19981113	
			WO 1999-US25570 W	19991102	

AB The invention comprises a liquid composition which provides a drier feel and reduced leakage when used with certain types of applicators, especially an applicator having a porous surface, which composition is made by combining an active phase and a silicone phase. The active phase is made by combining: (a) 10-70 % of a selected glycol; (b) 0.1-10 % of a nonionic emulsifier having an HLB greater than 8; (c) 0.01-30 % of a cosmetically active ingredient; and (d) 0-20 % of ethanol and/or isopropanol. The silicone phase is made by combining: (a) 0.1-10 % of a selected emulsifier; (b) 0-30 % of a non-volatile silicone; (c) 0-30 % of a volatile silicone; and (d) 0-25% of an organic emollient; provided that, (a) the silicone phase contains ≥ 10 % silicone; (b) the ratio of silicone phase to the active phase is in the range of 1:1 to 1:4; and (c) the composition is processed to maintain a viscosity in the range of 2,000-200,000 cP. A clear antiperspirant composition was made by combining dimethicone copolyol (10% in cyclomethicone) (40.52 g); C12-15 alkyl benzoate (60.17 g); and cyclomethicone (49.83g) and mixing them at 500 rpm until the mixture was homogeneous to form Phase A. Phase B was made by combining an antiperspirant active (Westchlor ZR 35B 30% PG solution) (152.07 g), Polysorbate 80 (1.30 g), propylene glycol (146.82 g), ethanol (95% alc.) (45.06 g), and fragrance (5.02 g). Phase B was added to Phase A with stirring and the composition was allowed to sit overnight and placed in a package with a porous applicator.

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:722376 CAPLUS
DOCUMENT NUMBER: 132:298673
TITLE: Nebulizer-compatible liquid formulations for pulmonary delivery of glucocorticoids: pre-formulation studies
AUTHOR(S): Klyashchitsky, B.; Saidi, Z.; Saar, A.; Sedlak, D.; Szymkowiak, J.; Owen, A.
CORPORATE SOURCE: LDS Technologies, Inc., Boothwyn, PA, 19061, USA
SOURCE: Proceedings of the International Symposium on Controlled Release of Bioactive Materials (1999), 26th, 565-566
CODEN: PCRMEY; ISSN: 1022-0178
PUBLISHER: Controlled Release Society, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The determination of solubility in various solvents, oils, and surfactants and stability evaluation was valuable in the pre-formulation of glucocorticoid liquid composition development.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:661508 CAPLUS
DOCUMENT NUMBER: 129:281013
TITLE: Pharmaceutical compositions containing lamivudine and a preservative
INVENTOR(S): Nguyen, Ngoc-Anh Thi; Casey, Warren M.
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9842321	A2	19981001	WO 1998-EP1626	19980320 <--
WO 9842321	A3	19990107		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
TW 536403	B	20030611	TW 1998-87103841	19980316 <--
ZA 9802367	A	19990920	ZA 1998-2367	19980319 <--
CA 2286126	A1	19981001	CA 1998-2286126	19980320 <--
CA 2286126	C	20030812		
AU 9872084	A	19981020	AU 1998-72084	19980320 <--
AU 728461	B2	20010111		
US 6004968	A	19991221	US 1998-44896	19980320 <--
EP 969815	A2	20000112	EP 1998-919120	19980320 <--
EP 969815	B1	20050511		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9808060	A	20000308	BR 1998-8060	19980320 <--
EE 9900440	A	20000417	EE 1999-440	19980320 <--
EE 3996	B1	20030415		
IL 131917	A	20010111	IL 1998-131917	19980320 <--
HU 2000002982	A2	20010129	HU 2000-2982	19980320 <--
HU 2000002982	A3	20011228		
HU 225600	B1	20070502		
JP 2001501974	T	20010213	JP 1998-544425	19980320 <--
JP 3264937	B2	20020311		
NZ 337798	A	20010330	NZ 1998-337798	19980320 <--
IL 138098	A	20030112	IL 1998-138098	19980320 <--
AP 1141	A	20030129	AP 1999-1657	19980320 <--
W: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW				
SK 283417	B6	20030701	SK 1999-1299	19980320 <--
AT 295150	T	20050515	AT 1998-919120	19980320
PT 969815	T	20050729	PT 1998-919120	19980320
ES 2239802	T3	20051001	ES 1998-919120	19980320
PL 190505	B1	20051230	PL 1998-336038	19980320
CZ 298008	B6	20070523	CZ 1999-3403	19980320
HR 980154	B1	20020630	HR 1998-154	19980323 <--
IN 1998CA00479	A	20050318	IN 1998-CA479	19980323
MX 9908690	A	20000131	MX 1999-8690	19990922 <--

NO 9904619	A	19991123	NO 1999-4619		19990923 <--
BG 64690	B1	20051230	BG 1999-103818		19991018
HK 1022853	A1	20050909	HK 2000-102154		20000407
PRIORITY APPLN. INFO.:			US 1997-42353P	P	19970324
			GB 1997-6295	A	19970326
			IL 1998-131917	A3	19980320
			WO 1998-EP1626	W	19980320

AB Oral antiviral formulations containing lamivudine, substantially free of EtOH and EDTA, contain parabens at pH >5.5 as preservatives. Thus, a liquid formulation contained lamivudine 10.00, sucrose 200.0, Me paraben 1.50 kg, Pr paraben 180, artificial strawberry flavor 800, artificial banana flavor 600, Na citrate-2H2O 11, anhydrous citric acid 1 g, NaOH or HCl to pH 6.0, propylene glycol 19.4, and H2O to 1000 L. This composition remained free from growth of inoculated bacteria, yeasts, and molds for 14-28 days.

L5 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:635637 CAPLUS
DOCUMENT NUMBER: 129:265476
TITLE: Stable particle in liquid formulations comprising sugar glass
INVENTOR(S): Roser, Bruce Joseph; Sen, Shevanti Devika
PATENT ASSIGNEE(S): Eastbridge Ltd., UK
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9841188	A2	19980924	WO 1998-GB817	19980318 <--
WO 9841188	A3	19981210		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2293682	A1	19980924	CA 1998-2293682	19980318 <--
CA 2293682	C	20070116		
AU 9865101	A	19981012	AU 1998-65101	19980318 <--
AU 722627	B2	20000810		
EP 1007000	A2	20000614	EP 1998-910875	19980318 <--
EP 1007000	B1	20060510		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
BR 9808920	A	20000801	BR 1998-8920	19980318 <--
NZ 337666	A	20010427	NZ 1998-337666	19980318 <--
JP 2002504090	T	20020205	JP 1998-540262	19980318 <--
AT 325605	T	20060615	AT 1998-910875	19980318
IN 1998MA00573	A	20070518	IN 1998-MA573	19980318
NO 9904508	A	19991117	NO 1999-4508	19990917 <--
US 6669963	B1	20031230	US 1999-380485	19991104
PRIORITY APPLN. INFO.:			GB 1997-5588	A 19970318
			WO 1998-GB817	W 19980318

AB A stable particle in liquid formulation comprising a discontinuous phase of microparticles is suspended in a continuous phase which is a non-aqueous liquid,

preferably biocompatible in which the microparticles are insol. The microparticles comprise finely powdered sugar glass selected from the group consisting of trehalose, palatinit, glucopyranosyl sorbitol, glucopyranosyl mannitol, lactitol and monosaccharide alcs. such as mannitol and inositol, holding at least one biomol. product, the biomol. product in the sugar glass either being in stable solid solution or being itself in suspension in the sugar glass. A monodisperse single-particle suspension of microparticles can be produced in the non-aqueous continuous liquid phase by inclusion in the continuous phase of at least one surfactant having a low or very low HLB. A solution containing trehalose 0.6, sodium sulfate 0.35 M, bovine serum albumin 0.75, zinc chloride 1, magnesium chloride 1 mM, and alkaline phosphatase 40 units/mL was spray dried. When the powder was stored at 37°, there was no loss of enzyme activity over 84 days of storage.

L5 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:650275 CAPLUS
DOCUMENT NUMBER: 127:298754
TITLE: Compositions comprising an HIV protease inhibitor such as VX 478 and a water soluble vitamin e compound such as vitamin E-TPGS
INVENTOR(S): Roy, Arup K.; Tillman, Lloyd Gary
PATENT ASSIGNEE(S): Glaxo Group Limited, UK; Roy, Arup K.; Tillman, Lloyd Gary
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9735587	A1	19971002	WO 1997-EP1438	19970321 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9702387	A	19971210	ZA 1997-2387	19970319 <--
US 6730679	B1	20040504	US 1997-820848	19970320
CA 2249336	A1	19971002	CA 1997-2249336	19970321 <--
CA 2249336	C	20051122		
AU 9721591	A	19971017	AU 1997-21591	19970321 <--
AU 724239	B2	20000914		
EP 906107	A1	19990407	EP 1997-914287	19970321 <--
EP 906107	B1	20030108		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9708238	A	19990803	BR 1997-8238	19970321 <--
CN 1225587	A	19990811	CN 1997-193229	19970321 <--
HU 9901887	A2	19991228	HU 1999-1887	19970321 <--
HU 9901887	A3	20000228		
JP 2000500504	T	20000118	JP 1997-534017	19970321 <--
JP 3117726	B2	20001218		
NZ 331645	A	20000228	NZ 1997-331645	19970321 <--
TW 455491	B	20010921	TW 1997-86103607	19970321 <--
CZ 289958	B6	20020515	CZ 1998-3035	19970321 <--
AT 230602	T	20030115	AT 1997-914287	19970321 <--

AP 1150	A	20030314	AP 1998-1343		19970321 <--
W: GH, GM, KE, LS, MW, SD, SZ, UG, ZW					
IL 126185	A	20030529	IL 1997-126185		19970321 <--
ES 2190528	T3	20030801	ES 1997-914287		19970321
EE 4093	B1	20030815	EE 1998-323		19970321
PL 187919	B1	20041130	PL 1997-328916		19970321
SK 284244	B6	20041201	SK 1998-1269		19970321
IN 1997DE00727	A	20050311	IN 1997-DE727		19970321
RO 119923	B1	20050630	RO 1998-1407		19970321
NO 9804386	A	19981120	NO 1998-4386		19980921 <--
NO 317639	B1	20041129			
KR 2000004919	A	20000125	KR 1998-707478		19980921 <--
BG 64457	B1	20050331	BG 1998-102838		19981012
HK 1016896	A1	20030711	HK 1999-102135		19990512
PRIORITY APPLN. INFO.:			US 1996-13893P	P	19960322
			GB 1996-6372	A	19960326
			US 1997-820848	A	19970320
			WO 1997-EP1438	W	19970321

AB Pharmaceutical formulations containing HIV protease inhibitors, specifically including 3S-[3R*(1R*,2S*)]-[3-[[(4-aminophenyl)sulfonyl](2-methylpropyl)-amino]-2-hydroxy-1-(phenylmethyl)propyl]carbamic acid, tetrahydro-3-furanyl ester (alternatively known as VX 478 or 141W94) (I), and a tocopherol, and their use in medical therapy are described. A liquid formulation was prepared containing I 150.0, α-tocopheryl PEG succinate (TPGS) 400.0, PEG 400 200.5, and propylene glycol 39.5 mg/capsule.

L5 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1996:313848 CAPLUS
DOCUMENT NUMBER: 124:352705
TITLE: Tastemasked liquid pharmaceuticals containing sugars and hydrogenated maltose and polyhydroxy alcohols
INVENTOR(S): Lienhop, Keith S.; Cuca, Robert C.; Riley, Thomas Charles, Jr.; Levinson, R. Saul
PATENT ASSIGNEE(S): Kv Pharmaceutical Corporation, USA
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 9603976	A1	19960215	WO 1995-US9709		19950801 <--
W: AU, CA, JP, MX, NZ					
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
CA 2172807	A1	19960215	CA 1995-2172807		19950801 <--
CA 2172807	C	19991012			
AU 9531548	A	19960304	AU 1995-31548		19950801 <--
US 5730997	A	19980324	US 1996-712436		19960911 <--
PRIORITY APPLN. INFO.:			US 1994-282495	A	19940801
			WO 1995-US9709	W	19950801

AB A substantially tasteless liquid pharmaceutical delivery system containing an active material and a high osmolarity aqueous system comprising (1) water; (2) about 20% to about 45% by weight sugar derivative; (3) about 10% to about 15% by weight hydrogenated maltose syrup; and (4) about 0% to about 35% by weight polyhydroxy alc. A tastemasked liquid formulation contained diphenhydramine.HCl 0.2111, water 16.4624, sorbitol solution 41.8179, maltitol solution 13.9287, propylene glycol 25.8670, sodium gluconate 0.1857, citric acid 0.2111, saccharin sodium

0.1013, magnasweet-180 0.0422, Me paraben 0.844, Pr paraben 0.0152, colors 0.0177, and flavor 1.0553%.

L5 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1994:452376 CAPLUS
DOCUMENT NUMBER: 121:52376
TITLE: Stabilized isothiazolone liquid formulation
INVENTOR(S): Sano, Yoichi; Tsuji, Katsuji; Katayama, Sakae
PATENT ASSIGNEE(S): Katayama Chemical Inc., Japan
SOURCE: U.S., 5 pp. Cont. of U.S. Ser. No. 745,250, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5306725	A	19940426	US 1992-970231	19921030 <--
PRIORITY APPLN. INFO.:			US 1991-745250 B1	19910814
OTHER SOURCE(S):	MARPAT 121:52376			

GI



I

AB A Stabilized isothiazolone liquid formulation including: an isothiazolone compound represented by the formula (I): (where X represents a H atom or halogen atom, and Y represents a lower alkyl group), and a mixed solvent containing 50-99.9 weight% of a glycol type solvent and 50-0.1 weight% of an amide-type compound represented by the formula R1CONR2R3, where R1 represents a H atom or a lower alkyl group, R2 and R3 each represent a lower alkyl group, R1 and R3 each represent a lower alkyl group, R1 may bond to R2 or R3 to form a nitrogen-containing heterocycle, the compound of the formula I being dissolved in the mixed solvent of which amount is at least sufficient to dissolve it.

L5 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1993:598571 CAPLUS
DOCUMENT NUMBER: 119:198571
TITLE: Stabilized aqueous liquid formulations of phytase and their use in feed preparation for monogastric animals
INVENTOR(S): Barendse, Rudolfus Carolus Mari; Van Doesum, Johannes Henricus; Gouwens, Jacob; Van Paridon, Petrus Andreas
PATENT ASSIGNEE(S): Gist-Brocades N.V., Neth.
SOURCE: PCT Int. Appl., 23 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9316175	A1	19930819	WO 1993-EP356	19930212 <--
W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO,				

NZ, PL, RO, RU, SD, SK, UA, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE,
BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG

AU 9336284	A	19930903	AU 1993-36284		19930212 <--
EP 626010	A1	19941130	EP 1993-905244		19930212 <--
R: DE, DK, NL					
FI 9403707	A	19940810	FI 1994-3707		19940810 <--
PRIORITY APPLN. INFO.:			EP 1992-200414	A	19920213
			WO 1993-EP356	A	19930212

AB A stabilized liquid formulation of phytase contains a stabilizing agent, i.e. urea 1-10 weight/weight% or water-soluble polyol, such as sorbitol or glycerol. A feed composition for monogastric animals is prepared by treating the feed with the stabilized phytase formulation. The treatment releases P from the phytate, making it available to the animal.

L5 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1965:50780 CAPLUS
DOCUMENT NUMBER: 62:50780
ORIGINAL REFERENCE NO.: 62:8946c-d
TITLE: Metal-acid complexes with members of the tetracycline family. II. Development of stable preconstituted parenteral formulations
AUTHOR(S): Remmers, Edward G.; Barringer, William C.; Sieger, George M.; Doerschuk, Albert P.
CORPORATE SOURCE: Am. Cyanamid Co., Pearl River, NY
SOURCE: Journal of Pharmaceutical Sciences (1964), 53(12), 1534-6
CODEN: JPMSAE; ISSN: 0022-3549
DOCUMENT TYPE: Journal
LANGUAGE: English
AB cf. CA 62, 3888h. Al-Ca-gluconate complexes of tetracycline and 6-demethylchlortetracycline were prepared by previously described methods (loc. cit.) and made into stable liquid formulations suitable for intramuscular and intravenous use by solution in aqueous propylene glycol (I). The formulations were well tolerated at therapeutic levels and gave adequate blood levels. Prepns. containing the 1:3:1:6 (molar ratio) antibiotic-Al-Ca-gluconate complex in 50-75% I at pH 8.5 were the most satisfactory and retained initial potencies at both room and elevated temps. for prolonged periods.

=> Log Off H
SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 10:38:16 ON 20 FEB 2008

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEGS1646

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America

```
NEWS  2  AUG 06  CAS REGISTRY enhanced with new experimental property tags
NEWS  3  AUG 06  FSTA enhanced with new thesaurus edition
NEWS  4  AUG 13  CA/CAplus enhanced with additional kind codes for granted
                 patents
NEWS  5  AUG 20  CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS  6  AUG 27  Full-text patent databases enhanced with predefined
                 patent family display formats from INPADOCDB
NEWS  7  AUG 27  USPATOLD now available on STN
NEWS  8  AUG 28  CAS REGISTRY enhanced with additional experimental
                 spectral property data
NEWS  9  SEP 07  STN AnaVist, Version 2.0, now available with Derwent
                 World Patents Index
NEWS 10  SEP 13  FORIS renamed to SOFIS
NEWS 11  SEP 13  INPADOCDB enhanced with monthly SDI frequency
NEWS 12  SEP 17  CA/CAplus enhanced with printed CA page images from
                 1967-1998
NEWS 13  SEP 17  CAplus coverage extended to include traditional medicine
                 patents
NEWS 14  SEP 24  EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 15  OCT 02  CA/CAplus enhanced with pre-1907 records from Chemisches
                 Zentralblatt
NEWS 16  OCT 19  BEILSTEIN updated with new compounds
NEWS 17  NOV 15  Derwent Indian patent publication number format enhanced
NEWS 18  NOV 19  WPIX enhanced with XML display format
NEWS 19  NOV 30  ICSD reloaded with enhancements
NEWS 20  DEC 04  LINPADOCDB now available on STN
NEWS 21  DEC 14  BEILSTEIN pricing structure to change
NEWS 22  DEC 17  USPATOLD added to additional database clusters
NEWS 23  DEC 17  IMSDRUGCONF removed from database clusters and STN
NEWS 24  DEC 17  DGENE now includes more than 10 million sequences
NEWS 25  DEC 17  TOXCENTER enhanced with 2008 MeSH vocabulary in
                 MEDLINE segment
NEWS 26  DEC 17  MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 27  DEC 17  CA/CAplus enhanced with new custom IPC display formats
NEWS 28  DEC 17  STN Viewer enhanced with full-text patent content
                 from USPATOLD
NEWS 29  JAN 02  STN pricing information for 2008 now available
NEWS 30  JAN 16  CAS patent coverage enhanced to include exemplified
                 prophetic substances
NEWS 31  JAN 28  USPATFULL, USPAT2, and USPATOLD enhanced with new
                 custom IPC display formats
NEWS 32  JAN 28  MARPAT searching enhanced
NEWS 33  JAN 28  USGENE now provides USPTO sequence data within 3 days
                 of publication
NEWS 34  JAN 28  TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 35  JAN 28  MEDLINE and LMEDLINE reloaded with enhancements
NEWS 36  FEB 08  STN Express, Version 8.3, now available
NEWS 37  FEB 20  PCI now available as a replacement to DPCI


NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
             AND CURRENT DISCOVER FILE IS DATED 24 JANUARY 2008

NEWS HOURS    STN Operating Hours Plus Help Desk Availability
NEWS LOGIN    Welcome Banner and News Items
NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
```

research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:44:24 ON 20 FEB 2008

=> D Hist

     (FILE 'HOME' ENTERED AT 12:44:24 ON 20 FEB 2008)

=> Log off h
 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 12:44:53 ON 20 FEB 2008